Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Recent Health Care Deals, week ending 07.29.2016
AcquirerTargetPrice Shanghai Fosun Pharmaceutical Co. Ltd.Gland Pharma Ltd. $1.26 billion The Sanders Trust3 rehabilitation hospitals$111.5 million Laboratory Corp. of AmericaSequenom, Inc. $371 million Almirall, S.A.License to tildrakizumab in Europe$50 million Chartwell Retirement ResidencesTiffin House Retirement Residence$23.9... Read More »Kite Pharma Soars with Two T-Cell Acquisitions
Kite Pharma Inc. (NASDAQ: KITE) has been busy lately, announcing two separate license deals in the last week of July. On July 25, it acquired the exclusive worldwide rights to technology that advances the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells, also known as the ATO system, in a deal with the University of California, Los Angeles. In connection with this agreement, Kite entered into a sponsored research agreement with UCLA to support ongoing preclinical research for the ATO system. Two days later, Kite entered into a license agreement with the National Institute of Health for the license to its fully human anti-CD19 chimeric antigen... Read More »LabCorp Ventures into Prenatal Testing
LabCorp (NYSE: LH), the world’s leading healthcare diagnostics company, has acquired Sequenom Inc. (NASDAQ: SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, for a total purchase price of $371 million. In July of 2014, Sequenom purchased a license for non-invasive prenatal testing patents and applications from privately-held Mayo Medical Laboratories, and two months later it acquired intellectual property from privately-held Isis Innovation for non-invasive prenatal testing intellectual property. Today, Sequenom is the first laboratory to offer a clinically validated NIPT test (MaterniT®21), which has completed more than 500,000 tests to date. LabCorp’s most... Read More »BioClinica Adds Compass Research
Private equity-backed Bioclinica Inc. expanded its clinical research offerings with the July 2016 acquisition of Compass Research, LLC, a Florida-based clinical research site network that has direct access to a number of specialized populations with neurodegenerative disorders and other diseases found in aging demographics. The acquisition solidifies Bioclinica’s position as a leading global research network, and the only one with investigator sites in the United States, Europe, Latin America and Asia. Compass Research’s state-of-the-art facilities in Orlando have supported more than 1,300 trials and contributed to the FDA approval of more than 80 biopharmaceutical products.... Read More »Home Health & Hospice M&A Rebounds
There’s nothing sleepy about the Home Health & Hospice sector. Through the end of July 2016, this market has seen 35 transactions, putting this year on track to beat 2015’s total of 51 deals. Eleven of these 35 deals disclosed prices, totaling approximately $610 million spent so far this year. Sixty-percent of 2016’s home health & hospice acquirers have been other home health & hospice companies, with the busiest players being LHC Group (NASDAQ: LHCG) and privately held Jordan Health Services with two and three acquisitions, respectively. Five separate private equity firms announced five acquisitions, and Kindred Healthcare (NYSE: KND) announced four acquisitions in this... Read More »Recent Health Care Deals, week ending 07.22.2016
AcquirerTargetPrice Celgene CorporationCollaboration on immuno-oncology drugs$225 million Santen Pharmaceutical Co. Ltd.InnFocus Inc. $225 million Zimmer Biomet HoldingsMedtech SA$132.9 million Janssen BiotechLicense to IONIS-JBI1-2.5Rx$10 million Center Management Group, LLCAssisted living community$4.25... Read More »Royal Philips Expands With Population Health Management
Royal Philips (NYSE: PHG), the leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, has just acquired Georgia-based Wellcentive, Inc., a privately-held provider of cloud-based population health management and data analytics solutions for physicians and their organizations, for an undisclosed price. Wellcentive’s capabilities include importing, aggregating and analyzing clinical, claims and financial data across healthcare and hospital systems to allow providers to enhance their coordinated care delivery to satisfy new requirements and reimbursement models. Wellcentive’s applications will be assimilated into the Philip’s HealthSuite Cloud. This... Read More »Kroger Gobbles Up ModernHEALTH
Specialty pharmacy deals are usually few and far between. But this year, we’ve seen six deals announced in the first seven months. The most recent is from Kroger Co. (NYSE: KR), the giant food and consumer goods retailer. Kroger acquired Modern HC Holdings, the parent company of ModernHEALTH, and plans to merge it with its own specialty pharmacy subsidiary, Axium Pharmacy Holdings. Financial terms were not disclosed. Specialty pharmacy ModernHEALTH has been a portfolio company of Altamont Capital Partners since July 2012, and has grown considerably with Altamont’s help. As Modern Healthcare, the company served customers with complex pharmaceutical therapies, including HIV,... Read More »Managed Care Mega-Deals Not Too Big to Fail
2015 is about to lose even more of its M&A luster, it seems. Some $91 billion is about to disappear from the record-setting spending on healthcare M&A, thanks to the potential unraveling of two managed care mega-mergers. Bloomberg is reporting that the U.S. Department of Justice plans to file lawsuits seeking to halt the mergers of Aetna (NYSE: AET) and Humana (NYSE: HUM) for $37 billion, and Anthem (NYSE: ANTM) with Cigna (NYSE: CI), for $54.2 billion. For healthcare M&A wonks, 2015 set new records in deal volume, with more than 1,500 deals, and deal value, at $397 billion. The dollar total would have been even higher, at $564 billion, if Pfizer (NYSE: PFE) hadn’t walked... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
